What question did this study set out to answer?

To determine whether antihypertensive monotherapy with the ACE inhibitors captopril or enalapril induces regression of left ventricular hypertrophy in non-dialyzed patients with chronic renal failure.

May 1, 1997Nephrology Dialysis TransplantationOpen Access

ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure

View Full Paper

Ask AI

Bookmark

Authors

ADA. I. DyadykDonetsk National Medical University ABA. E. BagriyMinistry of Health of the Russian Federation ИЛИгорь Григорьевич Лебедь

Discussion

Member takes

Implication

ACEI monotherapy may regress LV mass in pre-dialysis CKD with hypertension; leaves open effects on clinical outcomes.

Key Points

To determine whether antihypertensive monotherapy with the ACE inhibitors captopril or enalapril induces regression of left ventricular hypertrophy in non-dialyzed patients with chronic renal failure.
Prospective randomized trial of 72 undialyzed patients with chronic renal failure, mild-to-moderate hypertension, and left ventricular hypertrophy assigned to captopril (n = 36) or enalapril (n = 36).
Assessed blood pressure, echocardiographic parameters, and Doppler measurements at baseline, 6 months, and 12 months of follow-up.
Left ventricular mass index decreased by 12% at 6 months and 20% at 12 months in the captopril arm, and by 14% at 6 months and 19% at 12 months in the enalapril arm.
Both treatments produced significant improvement in left ventricular filling dynamics without any deterioration in systolic performance, while six patients experienced adverse effects such as cough, rash, taste alterations, or gastric intolerance.

Cite This Study

Dyadyk et al. (1997) studied this question.

synapsesocial.com/papers/6a712b1e8031ec7bb1dccdef https://doi.org/10.1093/ndt/12.5.945

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

May 1, 1997Nephrology Dialysis TransplantationOpen Access

ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure

View Full Paper

Ask AI

Bookmark

Authors

ADA. I. DyadykDonetsk National Medical University ABA. E. BagriyMinistry of Health of the Russian Federation ИЛИгорь Григорьевич Лебедь

Discussion

Member takes

Implication

ACEI monotherapy may regress LV mass in pre-dialysis CKD with hypertension; leaves open effects on clinical outcomes.

Key Points

To determine whether antihypertensive monotherapy with the ACE inhibitors captopril or enalapril induces regression of left ventricular hypertrophy in non-dialyzed patients with chronic renal failure.
Prospective randomized trial of 72 undialyzed patients with chronic renal failure, mild-to-moderate hypertension, and left ventricular hypertrophy assigned to captopril (n = 36) or enalapril (n = 36).
Assessed blood pressure, echocardiographic parameters, and Doppler measurements at baseline, 6 months, and 12 months of follow-up.
Left ventricular mass index decreased by 12% at 6 months and 20% at 12 months in the captopril arm, and by 14% at 6 months and 19% at 12 months in the enalapril arm.
Both treatments produced significant improvement in left ventricular filling dynamics without any deterioration in systolic performance, while six patients experienced adverse effects such as cough, rash, taste alterations, or gastric intolerance.

Cite This Study

Dyadyk et al. (1997) studied this question.

synapsesocial.com/papers/6a712b1e8031ec7bb1dccdef https://doi.org/10.1093/ndt/12.5.945

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark